ClinicalTrials.gg
CompletedNCT00599001Updated Apr 16, 2019

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

A Phase 1 interventional study of SD-101 and placebo in Healthy, sponsored by Dynavax Technologies Corporation. Completed at 1 site in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-16.

Sponsored by Dynavax Technologies Corporation (part of Sanofi) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

The main purpose of this study is to assess the safety, tolerability, and biological activity of SD-101 compared with placebo in healthy male volunteers.

Read the detailed description

This is a Phase 1, randomized, single-blind, placebo-controlled study of five escalating dose levels of SD-101 in healthy male volunteers. The objectives of the study are to assess the safety, tolerability, pharmacokinetic profile, and pharmacodynamics of SD-101. Approximately 40 subjects will participate.

Once subjects have been consented, screened, and assigned to one of the dose levels of SD-101, subjects will receive a single subcutaneous injection of either SD-101 or placebo (PBS) in a ratio of 6:2.

Safety and tolerability will be evaluated by occurrence of adverse events, blood and urine laboratory tests, physical examination findings, vital signs , and electrocardiogram findings. Pharmacodynamics will be evaluated by levels of blood biomarkers and serum cytokines, and flow cytometric cell counts. Pharmacokinetics will be evaluated by levels of study drug in serum.

02

Conditions studied

  • Healthy

Keywords

  • healthy volunteer
  • research subjects
  • Immunostimulatory sequence (ISS)
  • phase 1
03

In context

Lead sponsor

Dynavax Technologies Corporation is the lead sponsor of 25 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.

First submitted before Dynavax Technologies Corporation became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed, written, must be obtained from the subjects before any study-specific procedures are performed.
  • Subject must be male and 18 years of age or older.
  • Subject must be willing to submit to a urine drug screen and agree to abstain from alcohol, caffeine, and tobacco during the required stay in the Phase I Unit.
  • Subject must be willing to abide by the rules of the Phase 1 Unit.
  • Subjects whose sexual partners are of must agree to use an effective method of (i.e., chemical contraceptives, barrier plus spermicide, intrauterine device) during the treatment phase and for 14 days post treatment.
  • Must be negative for and C and (HIV).

Exclusion criteria

Exclusion Criteria:

  • Females.
  • active, acute, or chronic illness.
  • History of coagulation or bleeding disorders.
  • Clinically significant chronic or recent (within 21 days of dosing) acute gastrointestinal disorder with nausea, vomiting or diarrhea as a major symptom.
  • Received any vaccine within 3 weeks of study entry or plans to be vaccinated within 6 weeks after study injection.
  • History of significant cardiovascular or cerebrovascular disease.
  • History of evaluation for disease including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma or thyroiditis.
  • Significant psychiatric illness that could potentially interfere with the assessments during this study.
  • Subjects who have had prior surgery or a major infection within 6 months of dosing.
  • History of medications within 7 days of dosing, except vitamins and/or minerals.
  • History of Gilbert's disease.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Escalating Dose of SD-101

    Drug: SD-101

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • DrugSD-101

    Single subcutaneous escalating dose

  • Drugplacebo

    placebo

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with and the amplitude and timing of adverse events, proportion of subjects with and the grade and timing of abnormal lab values, and proportion of subjects with and timing of changes in physical exam findings and vital signs

    Time frame: Up to 7 days after dosing

Secondary outcomes

  1. Pharmacokinetic parameters

    Time frame: Up to 24 hours after dosing

  2. Levels of serum cytokines

    Time frame: Up to 7 days after dosing

  3. Levels of blood biomarkers (interferon-alpha inducible genes)

    Time frame: Up to 7 days after dosing

07

Study locations

1 site
  • Healthcare Discoveries, Inc.
    San Antonio, Texas 78209, United States
08

References and documents

Related links

Individual participant data

Plan to share: Undecided — No Change to status of this study.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2008
First posted
Jan 23, 2008
Start
Jan 2008
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Last update
Apr 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00599001
Responsible party
Sponsor
First posted
Jan 23, 2008
Start date
Jan 2008
Primary completion
Mar 2008
Completion
Mar 2008
Last update
Apr 16, 2019

Study contacts

Dennis Ruff, MD
principal investigator · Healthcare Discoveries, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nelitolimod

Start the discussion